Cosette Pharmaceuticals Announces Acquisition of Mayne Pharma, Transforming Company into a Leader in Women’s Health and Dermatology
Cosette Pharmaceuticals has announced a definitive agreement to acquire Mayne Pharma Group for approximately USD $430 Million at AUD$7.40 per share. The transaction is expected to close in Q2 2025.
The acquisition will transform Cosette into a leading player in women's health and dermatology in the U.S., combining Cosette's 350+ strong team with Mayne Pharma's 480+ workforce. The merged entity will operate two FDA-approved manufacturing facilities in Lincolnton, North Carolina and Salisbury, South Australia.
Post-acquisition, Cosette will market 12 patent-protected products including notable brands such as VYLEESI®, INTRAROSA®, NEXTSTELLIS®, ANNOVERA®, BIJUVA®, IMVEXXY® and RHOFADE®. The transaction has received approval from both companies' Boards of Directors, with Mayne Pharma's Board unanimously recommending shareholders vote in favor.
Cosette Pharmaceuticals ha annunciato un accordo definitivo per acquisire Mayne Pharma Group per circa 430 milioni di USD a AUD$7,40 per azione. Si prevede che la transazione si chiuda nel secondo trimestre del 2025.
L'acquisizione trasformerà Cosette in un attore principale nella salute delle donne e nella dermatologia negli Stati Uniti, combinando il team di oltre 350 persone di Cosette con la forza lavoro di oltre 480 di Mayne Pharma. L'entità risultante opererà due impianti di produzione approvati dalla FDA a Lincolnton, Carolina del Nord e Salisbury, Australia del Sud.
Dopo l'acquisizione, Cosette commercializzerà 12 prodotti protetti da brevetto, inclusi marchi noti come VYLEESI®, INTRAROSA®, NEXTSTELLIS®, ANNOVERA®, BIJUVA®, IMVEXXY® e RHOFADE®. La transazione ha ricevuto l'approvazione dai Consigli di Amministrazione di entrambe le aziende, con il Consiglio di Mayne Pharma che raccomanda all'unanimità agli azionisti di votare a favore.
Cosette Pharmaceuticals ha anunciado un acuerdo definitivo para adquirir Mayne Pharma Group por aproximadamente 430 millones de USD a AUD$7.40 por acción. Se espera que la transacción se cierre en el segundo trimestre de 2025.
La adquisición transformará a Cosette en un actor líder en la salud de la mujer y la dermatología en EE. UU., combinando el equipo de más de 350 personas de Cosette con la fuerza laboral de más de 480 de Mayne Pharma. La entidad fusionada operará dos instalaciones de fabricación aprobadas por la FDA en Lincolnton, Carolina del Norte y Salisbury, Australia del Sur.
Después de la adquisición, Cosette comercializará 12 productos protegidos por patentes, incluidos marcas notables como VYLEESI®, INTRAROSA®, NEXTSTELLIS®, ANNOVERA®, BIJUVA®, IMVEXXY® y RHOFADE®. La transacción ha recibido la aprobación de las Juntas Directivas de ambas compañías, con la Junta de Mayne Pharma recomendando unánimemente a los accionistas que voten a favor.
코제트 제약은 메인 파마 그룹을 약 4억 3천만 달러에 주당 AUD$7.40로 인수하기 위한 최종 계약을 발표했습니다. 이번 거래는 2025년 2분기에 마무리될 것으로 예상됩니다.
이번 인수로 코제트는 미국에서 여성 건강 및 피부과 분야의 선도적인 기업으로 자리매김하게 되며, 코제트의 350명 이상의 강력한 팀과 메인 파마의 480명 이상의 인력을 결합하게 됩니다. 합병된 회사는 노스캐롤라이나주 링컨턴과 호주 남부의 솔즈베리에서 FDA 승인을 받은 두 개의 제조 시설을 운영할 것입니다.
인수 후 코제트는 VYLEESI®, INTRAROSA®, NEXTSTELLIS®, ANNOVERA®, BIJUVA®, IMVEXXY® 및 RHOFADE®와 같은 주목할 만한 브랜드를 포함하여 12개의 특허 보호 제품을 판매할 것입니다. 이번 거래는 양사 이사회의 승인을 받았으며, 메인 파마 이사회는 주주들에게 찬성 투표를 권장했습니다.
Cosette Pharmaceuticals a annoncé un accord définitif pour acquérir Mayne Pharma Group pour environ 430 millions USD à AUD$7,40 par action. La transaction devrait se clôturer au deuxième trimestre de 2025.
L'acquisition transformera Cosette en un acteur majeur de la santé des femmes et de la dermatologie aux États-Unis, combinant l'équipe de plus de 350 personnes de Cosette avec la main-d'œuvre de plus de 480 personnes de Mayne Pharma. L'entité fusionnée exploitera deux installations de fabrication approuvées par la FDA à Lincolnton, Caroline du Nord et Salisbury, Australie du Sud.
Après l'acquisition, Cosette commercialisera 12 produits protégés par des brevets, y compris des marques notables telles que VYLEESI®, INTRAROSA®, NEXTSTELLIS®, ANNOVERA®, BIJUVA®, IMVEXXY® et RHOFADE®. La transaction a été approuvée par les conseils d'administration des deux entreprises, le conseil de Mayne Pharma recommandant à l'unanimité aux actionnaires de voter en faveur.
Cosette Pharmaceuticals hat eine endgültige Vereinbarung zur Übernahme von Mayne Pharma Group für etwa 430 Millionen USD zu AUD$7,40 pro Aktie bekannt gegeben. Es wird erwartet, dass die Transaktion im 2. Quartal 2025 abgeschlossen wird.
Die Übernahme wird Cosette zu einem führenden Akteur im Bereich Frauengesundheit und Dermatologie in den USA machen, indem das über 350-köpfige Team von Cosette mit der über 480-köpfigen Belegschaft von Mayne Pharma kombiniert wird. Das fusionierte Unternehmen wird zwei von der FDA genehmigte Produktionsstätten in Lincolnton, North Carolina und Salisbury, South Australia betreiben.
Nach der Übernahme wird Cosette 12 patentgeschützte Produkte vermarkten, darunter bemerkenswerte Marken wie VYLEESI®, INTRAROSA®, NEXTSTELLIS®, ANNOVERA®, BIJUVA®, IMVEXXY® und RHOFADE®. Die Transaktion wurde von den Vorständen beider Unternehmen genehmigt, wobei der Vorstand von Mayne Pharma einstimmig empfiehlt, dass die Aktionäre zustimmen.
- Acquisition valued at USD $430 Million strengthens market position
- Portfolio expansion to 12 patent-protected products in women's health and dermatology
- Combined workforce of 830+ employees enhancing operational capabilities
- Addition of two FDA-approved manufacturing facilities expanding production capacity
- Access to international markets through Mayne Pharma's established presence
- Significant capital expenditure of USD $430 Million required for acquisition
- Integration risks between two large organizations with different operational structures
- Transaction completion subject to regulatory and shareholder approvals
Insights
The USD $430 million acquisition of Mayne Pharma by Cosette Pharmaceuticals represents a strategic consolidation in the specialty pharmaceutical sector, particularly noteworthy for its focus on high-margin therapeutic areas. The transaction's structure and valuation reflect a calculated approach to market expansion and portfolio optimization.
The deal's strategic value centers on three key pillars:
- Portfolio Expansion: The acquisition brings 12 patent-protected products into Cosette's portfolio, significantly strengthening its intellectual property position. These assets, particularly in women's health and dermatology, represent sustainable revenue streams with patent protection providing competitive barriers.
- Operational Integration: The combined entity will leverage two FDA-approved manufacturing facilities in North Carolina and South Australia, creating a robust global supply chain infrastructure. The merger of the companies' workforces (350+ from Cosette and 480+ from Mayne) creates a substantial commercial organization with enhanced market reach.
- Market Position Enhancement: The transaction transforms Cosette into a leading player in women's health and dermatology in the U.S., with expanded international market access. The combination of Cosette's portfolio with Mayne's commercial expertise should drive market penetration and revenue growth.
The integration presents both opportunities and execution risks. While the complementary nature of the businesses suggests potential synergies, managing the integration of two significant operations across different geographies will require careful execution. The unanimous board approval and structured approach to regulatory clearances indicate a well-planned integration strategy.
The timing of the deal, with expected closure in Q2 2025, allows for appropriate regulatory review while maintaining momentum. The transaction's success will largely depend on the effective integration of commercial operations and the ability to leverage the combined patent portfolio for market expansion.
-- Acquisition Propels Cosette Into One Of The Leading Companies In Women’s Health and Dermatology in the
-- Highly Complementary Business Strengthens Cosette’s Portfolio, Commercial and Manufacturing Footprint and Expands Geographic Reach --
-- Utilizing Mayne Pharma’s Impressive Commercial and Sales Track Record to Drive Further Growth and Enhanced Patient Access --
(Photo: Business Wire)
“This acquisition marks a transformational step for Cosette, adding patented, high-growth products to solidify our leadership in women’s health in the
“Joining the Cosette team amplifies our shared mission to improve lives through innovative and accessible Women’s health and dermatology medicines,” said Shawn Patrick O’Brien, CEO, Mayne Pharma. “This transaction represents a unique opportunity for our employees, customers, and patients. Together, we will extend the reach of important therapies, drive innovation, and improve patient access.”
Transaction Rationale
-
Strengthens Cosette’s dermatology and women’s health businesses
The combination will create a leading women’s health and dermatology focused pharmaceuticals company in theU.S. with an established presence in international markets, utilizing the strengths of two industry players to drive innovation and expand access to women’s health therapies.
-
Expands Cosette’s commercial and operational capabilities
Cosette will utilize its market-leading commercial and operational capabilities, backed by its 350+ strong team and a leading portfolio of women’s health and dermatology products alongside Mayne Pharma’s complementary strength in these specialty areas. Mayne Pharma is backed by a 480+ strong team, including highly effective and successful sales and marketing teams in both specialties. The combined company will have two state-of-the-art FDA -approved manufacturing sites – one each inLincolnton, North Carolina andSalisbury ,South Australia – to service patients globally.
-
Adds multiple sustainable and growing patent-protected products
Upon close, Cosette will market 12 patent-protected products focused on women’s health and dermatology, including leading brands such as VYLEESI®, INTRAROSA®, NEXTSTELLIS®, ANNOVERA®, BIJUVA®, IMVEXXY® and RHOFADE®, and several programs in clinical development.
Terms of the Transaction
The transaction, which comprises the acquisition of
Cosette is being advised by Santander US Capital Markets LLC and UBS Investment Bank as financial advisers and Ropes & Gray LLP and Corrs Chambers Westgarth as legal advisers.
Mayne Pharma is being advised by Jefferies Australia as financial adviser and Gilbert + Tobin and Arnold & Porter as legal advisers.
About Cosette Pharmaceuticals
Cosette Pharmaceuticals, Inc. is a
VYLEESI®, CLOMID®, INTRAROSA®, AMBIEN®, AMBIEN® CR, WELCHOL®, AZOR®, TRIBENZOR®, BENICAR®, BENICAR® HCT, EFFIENT®, EVOXAC®, ANUCORT-HC®, PROMETHEGAN®, and MIGERGOT® are trademarks of Cosette Pharmaceuticals, Inc.
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma has a 40- year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialized in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit Maynepharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250220569463/en/
Cosette Pharmaceuticals:
Media:
media@cosettepharma.com
Source: Cosette Pharmaceuticals, Inc.
FAQ
What is the acquisition price for Mayne Pharma by Cosette Pharmaceuticals?
When is the Cosette-Mayne Pharma acquisition expected to close?
Which key brands will Cosette acquire through the Mayne Pharma purchase?
How many manufacturing facilities will the combined Cosette-Mayne company have?
What is the total workforce size after Cosette's acquisition of Mayne Pharma?
